Tags: FDA | Approves | Ecstasy | Study | Cancer | Patients

FDA Approves Ecstasy Study in Cancer Patients

Tuesday, 28 December 2004 12:00 AM

The small, four-month study is expected to begin in early spring. It will test the drug's effects on 12 cancer patients from Lahey Clinic Medical Center in the Boston area. The research is being sponsored by Multidisciplinary Association for Psychedelic Studies, a nonprofit group that plans to raise $250,000 to fund it.

MAPS, on its web site, touted the study's approval, saying ``the longest day of winter has passed, and maybe so has the decades-long era of resistance to psychedelic research.''

The FDA would not comment, but this will be the second FDA-approved study using Ecstasy this year. South Carolina researchers are studying the effects of Ecstasy on 20 patients suffering from post-traumatic stress disorder.

Ecstasy, known scientifically as MDMA for methylenedioxymethamphetamine, is a chemical cousin of methamphetamine and typically induces feelings of euphoria, increased energy and sexual arousal. But it also suppresses appetite, thirst and the need to sleep, and in high doses can sharply increase body temperature, leading to kidney and heart failure, and death.

It peaked in 2001 as a trendy drug used by youth at gatherings called ``raves'' and dance clubs.

Halpern, who has done other research on the effects of hallucinogenic drugs, said that some, when used properly, can have medical benefits. He said that unlike LSD, Ecstasy is ``ego-friendly,'' and unlike some pain medications it does not oversedate people and make them foggy and unsteady.

Instead, he said, it can reduce stress and increase empathy. There are anecdotal reports, he said, of people dying of cancer who take Ecstasy and are able to talk to their family and friends about death and other subjects they couldn't broach before.

``I'm hoping that we can find something that can be of use for people in their remaining days of life,'' he said. If there are no significant problems, he said broader studies would follow this one.

In addition to FDA approval, the study has also received review board authorization from Lahey Clinic and Harvard Medical School's psychiatric facility, McLean Hospital. Halpern is awaiting a license from the federal Drug Enforcement Administration.

It has been more than 40 years since Harvard has been the site of psychedelic drug research, including the infamous LSD studies of Timothy Leary in 1963 and the Good Friday Experiment in 1965, done by Leary's student Walter Pahnke, studying the effects of psilocybin mushrooms on religious people.

But ``this is not about trying to create some sensationalistic storm,'' Halpern said. ``This is about trying to help these patients in a meaningful way.''

103

© 2019 Newsmax. All rights reserved.

   
1Like our page
2Share
Pre-2008
The small, four-month study is expected to begin in early spring. It will test the drug's effects on 12 cancer patients from Lahey Clinic Medical Center in the Boston area. The research is being sponsored by Multidisciplinary Association for Psychedelic Studies, a nonprofit...
FDA,Approves,Ecstasy,Study,Cancer,Patients
420
2004-00-28
Tuesday, 28 December 2004 12:00 AM
Newsmax Media, Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved